Deutsche Bank is out with its report on Stryker SYK, maintaining Hold on SYK.
In a note to clients, Deutsche Bank writes, "Over the past few years, Stryker has actively shifted its business mix away from orthopedics through acquisitions, most recently and notably Boston Scientific's neurovascular business. The diversified business model has proven to be increasingly valuable at the present time as the orthopedic market outlook continues to be sluggish. However, trading at 16x 2011 EPS estimates, a premium to its peers and the market, we believe the value is already reflected and shares offer little relative upside from current levels. We maintain our Hold rating."
Deutsche Bank has a $59 PT on SYK,
SYK closed yesterday at $58.37, up 1.34% from Monday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in